Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts PHILADELPHIA and OXFORD, United Kingdom, July 18, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of...

Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO - Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts -  - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OXFORD,...